Opus Genetics

IRD · NASDAQ

$4.01+$0.19 (+4.97%)TodayMarket closed · Oct 20, 7:53 PM ET

Prev close $3.82

IRD analyst rating

BuyConsensus of 14 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy14
Hold0
Underperform0
Sell0

12-month price target · 19 analysts

Average $12.98 (+223.6% upside)

Low: $8.08
Now: $4.01
High: $21.00

Upgrades and downgrades

The latest rating actions, newest first

IRD analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Citizens	Oct 16, 2026	Maintains	Market Outperform	$17.00	47%
Jones Trading	Oct 6, 2026	Maintains	Buy	$10.00 → $17.00	—
Chardan Capital	Oct 2, 2026	Maintains	Buy	$16.00	45%
Wedbush	Sep 10, 2026	Maintains	Outperform	$10.00 → $13.00	40%
Oppenheimer	Sep 9, 2026	Maintains	Outperform	$10.00 → $20.00	45%
HC Wainwright & Co.	Sep 9, 2026	Maintains	Buy	$8.00	47%
BTIG	Sep 9, 2026	Maintains	Buy	$12.00	30%
Chardan Capital	Sep 9, 2026	Maintains	Buy	$13.00 → $16.00	45%
RBC Capital	Aug 7, 2026	Maintains	Outperform	$10.00 → $9.00	44%
TD Cowen	Jul 29, 2026	Initiates	Buy	—	42%

The case for and against

Updated Oct 14, 2026

Bull case

Opus Genetics is supported by a sharper regulatory and clinical path for OPGx-BEST1 after the FDA aligned on a randomized, sham-controlled pivotal design with a more achievable responder threshold of mean microperimetry improvement of at least 3 dB across five loci plus a patient-reported outcome. The company’s outlook is strengthened by Cohort 2’s higher-dose, over-enrolled study in 2026, with dosing completion in 4Q26 and 3-month top-line data expected in 2Q27, while current cash burn is said to extend into 2029. Beyond BEST1, OPGx-LCA5 is the most advanced registrational opportunity with dosing planned to begin in 4Q26, and four clinical readouts expected in 2027 across BEST1, LCA5, RDH12, and MERTK could validate a broader IRD platform.

Bear case

Opus Genetics is a highly speculative gene-therapy story whose value depends heavily on two lead programs, OPGx-LCA5 and OPGx-BEST1, both still exposed to clinical, regulatory, and commercialization risk. Although FDA alignment and the five-patient Cohort 1 signal for OPGx-BEST1 are encouraging, the data remain small, open-label, and uncontrolled, while OPGx-LCA5 has completed enrollment in its six-month run-in period but has not yet begun treatment dosing. With only one partnered, revenue-generating product, significant losses since inception, and a need for substantial capital despite a cash runway expected into 2029, dilution, delays, or weak efficacy could materially pressure the business.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.